Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Alpha-Synuclein


Brief Information

Name:Synuclein alpha
Target Synonym:Truncated Alpha Synuclein,Α-Synuclein,Non-A Beta Component Of AD Amyloid,Synuclein Alpha-140,I+/--Synuclein,α-Synuclein,PARK4,PD1,alpha-Synuclein,Synuclein, Alpha (Non A4 Component Of Amyloid Precursor),Non A-Beta Component Of AD Amyloid,PARK1,SNCA,Synuclein Alpha,NACP,Parkinson Disease (Autosomal Dominant, Lewy Body) 4,Non-A4 Component Of Amyloid Precursor,Non A4 Component Of Amyloid Precursor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CHEK-ATP085-Cell-based assay
 Alpha-synuclein FACS

FACS analysis of Alpha-synuclein (GFP) on HEK293/Human Alpha-synuclein (GFP) Stable Cell Line.
HEK293/Human Alpha-synuclein (GFP) Stable Cell Line was red line, negative control HEK293 cells was grey line (QC tested).

 Alpha-synuclein ELISA

Immobilized Human Alpha-Synuclein (A53T), His Tag (Cat. No. ALN-H51H5) at 1 μg/mL (100 μL/well) can bind Synuclein alpha/beta Monoclonal Antibody with a linear range of 1-31 ng/mL (QC tested).

Alpha-synuclein MALS images

The purity of Human Alpha-Synuclein (E46K), Tag Free (Cat. No. ALN-H5117) is more than 95% and the molecular weight of this protein is around 13-20 kDa verified by SEC-MALS.

Synonym Name



Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. Participates as a monomer in synaptic vesicle exocytosis by enhancing vesicle priming, fusion and dilation of exocytotic fusion pores. Mechanistically, acts by increasing local Ca2+ release from microdomains which is essential for the enhancement of ATP-induced exocytosis. Acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5. This chaperone activity is important to sustain normal SNARE-complex assembly during aging. Plays also a role in the regulation of the dopamine neurotransmission by associating with the dopamine transporter (DAT1) and thereby modulating its activity.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Buntanetap ANVS-405; ANVS-401 Phase 3 Clinical Raptor Pharmaceutical Down Syndrome; Chronic Traumatic Encephalopathy; Parkinson Disease; Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia Details
MEDI-1341 MEDI-1341; TAK- 341 Phase 2 Clinical Astrazeneca Plc, Takeda Pharmaceutical Co Ltd Parkinson Disease; Multiple System Atrophy Details
Lu AF-82422 (Lundbeck A/S) Lu AF-82422; Lu AF82422; Lu-AF82422 Phase 2 Clinical H. Lundbeck A/S, Genmab A/S Parkinson Disease; Multiple System Atrophy Details
Prasinezumab PRX-002; RG-7935; NEOD-002; RO-7046015 Phase 2 Clinical Prothena Parkinson Disease Details
Kenterin ENT-01; kenterin; Enterin-01 Phase 2 Clinical Enterin Inc Constipation; Parkinson Disease; Dementia Details
UB-312 UB-312 Phase 2 Clinical United Neuroscience Ltd Parkinsonian Disorders; Parkinson Disease; Multiple System Atrophy Details
PBT-434 PBT-434; ATH-434 Phase 2 Clinical Prana Biotechnology Ltd Multiple System Atrophy Details
MT101-5 MT101-5 Phase 2 Clinical Mthera Pharma Co Ltd Parkinson Disease Details
AMDX-2011P AMDX2011P; AMDX-2011P Phase 2 Clinical Amydis Inc Cerebral Amyloid Angiopathy; Glaucoma, Open-Angle; Parkinson Disease; Amyotrophic Lateral Sclerosis Details
ACI-7104 ACI-7104.056; ACI-7104 Phase 2 Clinical Ac Immune Sa Parkinson Disease Details
UCB-0599 UCB-1332; NPT200-11; UCB-0599 Phase 2 Clinical Neuropore Therapies Inc, Novartis Ag Parkinson Disease Details
ION-464 BIIB-101; IONIS-BIIB6 Rx; ION-464 Phase 1 Clinical Ionis Pharmaceuticals Inc Multiple System Atrophy Details
SAR-446159 ABL-301; SAR-446159 Phase 1 Clinical Abl Bio Inc Parkinson Disease Details
ACI-12589 ACI-12589; a-syn-PET tracer (AC Immune) Phase 1 Clinical Ac Immune Sa, Biogen Inc Parkinson Disease; Synucleinopathies Details
SNP201 SNP201; SNP-201 Phase 1 Clinical SciNeuro Pharmaceuticals Parkinson Disease Details
[18F]UCB-2897 Phase 1 Clinical Invicro Llc Parkinsonian Disorders; Parkinson Disease; Multiple System Atrophy Details
ACI-3847 ACI-3847; 18F-ACI-3847 Phase 1 Clinical Ac Immune Sa, Biogen Inc Parkinson Disease; Neurodegenerative Diseases Details
UCB-7853 UCB-7853 Phase 1 Clinical Ucb Biopharma Srl Parkinson Disease Details
Emrusolmin Anle-138b; TEV-56286 Phase 1 Clinical Modag Gmbh Parkinson Disease Details
Syneuro (Indus Biotech) Clinical Indus Biotech Pvt Ltd Parkinson Disease Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken